- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) locally advanced (unresectable) or metastatic breast cancer
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 2MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 1.8MB)
Capivasertib – November 2024
Capivasertib; Tablet 160 mg, Tablet 200 mg; Truqap®
Last updated
30 May 2025